{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007054","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.574581+00:00","generated_at":"2026-06-18T06:43:29.039724+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"KalVista reports Q3 net loss $21.3M; sebetralstat phase 3 enrollment >50%, data H2 2023","bullets":["Net loss $21.3M ($0.75 per share), no revenue; R&D $20.1M, G&A $6.9M.","Phase 3 KONFIDENT trial enrollment exceeds 50%; topline data expected H2 2023.","FDA guidance: no efficacy trials required for ODT sNDA; PMDA guidance for Japan.","Cash and securities $171.7M; $58M financing extends runway into 2025.","Phase 2 sebetralstat data published in The Lancet; CFO Palleiko promoted to President."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007054","json":"https://secwatch.observer/filing/0000950170-23-007054.json","markdown":"https://secwatch.observer/filing/0000950170-23-007054.md","text":"https://secwatch.observer/filing/0000950170-23-007054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023007054/0000950170-23-007054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023007054/kalv-20230309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T06:43:29.039724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}